20-May-2024
No headlines found.
iCAD Reports Financial Results for First Quarter Ended March 31, 2024
Globe Newswire (Wed, 15-May 8:00 AM ET)
UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
Globe Newswire (Wed, 8-May 9:49 AM ET)
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
Globe Newswire (Thu, 2-May 8:00 AM ET)
Globe Newswire (Thu, 11-Apr 8:00 AM ET)
Globe Newswire (Tue, 9-Apr 8:00 AM ET)
Globe Newswire (Mon, 8-Apr 4:29 PM ET)
Globe Newswire (Wed, 3-Apr 8:00 AM ET)
Globe Newswire (Tue, 2-Apr 8:00 AM ET)
Globe Newswire (Tue, 19-Mar 9:00 AM ET)
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
Globe Newswire (Tue, 12-Mar 4:01 PM ET)
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
Icad trades on the NASDAQ stock market under the symbol ICAD.
As of May 20, 2024, ICAD stock price declined to $1.64 with 133,665 million shares trading.
ICAD has a beta of 1.48, meaning it tends to be more sensitive to market movements. ICAD has a correlation of 0.03 to the broad based SPY ETF.
ICAD has a market cap of $43.22 million. This is considered a Sub-Micro Cap stock.
Last quarter Icad reported $5 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $514,000 and exceeded earnings estimates by $.01.
In the last 3 years, ICAD stock traded as high as $19.00 and as low as $1.05.
The top ETF exchange traded funds that ICAD belongs to (by Net Assets): VTI, VXF, IWC.
ICAD stock has underperformed the market in the last year with a return of +21.5%, while SPY returned +28.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ICAD shares. However, ICAD has outperformed the market in the last 3 month and 2 week periods, returning +13.5% and +14.7%, while SPY returned +7.0% and +2.6%, respectively. This indicates ICAD has been having a stronger performance recently.
ICAD support price is $1.67 and resistance is $1.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICAD stock will trade within this expected range on the day.